TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI®…
<!-- Name:DistributionId Value:8826808 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
BRIUMVI
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for…
<!-- Name:DistributionId Value:8799571 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3…
<!-- Name:DistributionId Value:8781303 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3…
<!-- Name:DistributionId Value:8748579 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the…
NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms…
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion twice-a-year…